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Haemoglobin C (HbC) is one of the commonest structural haemoglobin variants in human populations.
Although HbC causes mild clinical complications, its diagnosis and genetic counselling are important to
prevent inheritance with other haemoglobinopathies. Little is known about its contemporary distribution
and the number of newborns affected.We assembled a global database of population surveys. We then used
a Bayesian geostatistical model to create maps of HbC frequency across Africa and paired our predictions
with high-resolution demographics to calculate heterozygous (AC) and homozygous (CC) newborn
estimates and their associated uncertainty. Data were too sparse outside Africa for this methodology to be
applied. The highest frequencies were found inWest Africa but HbC was commonly found in other parts of
the continent. The expected annual numbers of AC and CC newborns in Africa were 672,117 (interquartile
range (IQR): 642,116-705,163) and 28,703 (IQR: 26,027-31,958), respectively. These numbers are about two
times previous estimates.
H
aemoglobin C (HbC) is a structural variant of normal haemoglobin (HbA) caused by an amino acid
substitution at position 6 of the b-globin chain (b6Glu-Lys)1. It is one of the most prevalent abnormal
haemoglobin mutations globally alongside haemoglobin S, which occurs at the same position (HbS;
b6Glu-Val), and haemoglobin E (HbE, b26Glu-Lys). In HbC heterozygote individuals (AC), this trait is
asymptomatic. Homozygosity (CC) causes clinically mild haemolytic anaemia, due to the reduced solubility
of the red blood cells which can lead to crystal formation2. HbC is mainly of clinical significance when
inherited in combination with HbS (sickle-haemoglobin C disease), causing chronic haemolytic anaemia and
intermittent sickle cell crises, slightly less severe or frequent than in homozygous HbS patients (SS), and
when co-inherited with b-thalassaemia (haemoglobin C-b thalassaemia), causing moderate haemolytic anae-
mia with splenomegaly3.
HbC allele frequencies above 15% have been described inWest African populations4. As for HbS, the selection
pressure resulting frommalaria protection has been suggested to explain the high prevalence of this polymorph-
ism in a number of populations (commonly referred to as the malaria hypothesis)5,6. It has been found that HbC
provides near full protection against Plasmodium falciparum malaria in homozygous (CC) individuals and
intermediate protection in heterozygous (AC) individuals7. Although these advantages (milder clinical severity
and protection from severe and fatal Plasmodium falciparum malaria in both AC and CC individuals) could
suggest that HbC has better fitness than HbS8,9, until the recent waves of human migration in the last few
centuries, its distribution was limited to a much smaller geographic area than that of HbS5.
HbC is now widespread10–13, and it is widely assumed that HbC expanded to its current distribution from a
unique origin in West Africa14–16, although an independent origin in southeast Asia has been suggested17,18. The
current distribution ofHbC is poorly documented4,19, yet this information is necessary to assess its contribution to
the increasing public health and economic burden of the haemoglobinopathies20. Here, as part of our efforts to
create an open access online database of selected inherited blood disorders and polymorphisms5,21–23, we have
reviewed the published literature and assembled representative population survey data on HbC allele frequencies
at the global scale. Following careful inclusion criteria and georeferencing of these data, this database formed
the evidence-base for a Bayesian model-based geostatistical (MBG) framework24,25 which we developed to predict
a continuous map of the distribution of HbC across Africa. Pairing these predictions with high resolution
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population data and national crude birth rates allowed the expected
numbers of newborns affected annually by HbC trait (AC) and dis-
ease (CC) to be estimated.
Results
Database. Our searches identified 174 data sources (listed in
Supplementary Information) with HbC data which allowed
calculation of an allele frequency for representative population
samples at specific locations. These included data for 445 spatially
unique locations (Figure 1). The total number of individuals tested
was 7,540,983. Sample sizes ranged from four individuals to
3,212,374. The mean sample size was 16,946 individuals. Some
82% of the population samples tested fewer than 1,000 individuals.
Although 45% of the population surveys were conducted on the
African continent, these represented only 5% of the total number
of individuals examined. Our searches revealed that about half (51%)
of the total 1,992 references from the online searches on HbC found
has been published after 1985, the publication year of Livingstone’s
latest database (Supplementary Figure S1)4. About 60%of the surveys
used for the present study pre-dated 1985. Amongst our 445
datapoints, an absence of HbC was reported in 48% of them. Few
surveys (n 5 7) indicating null frequencies within West Africa
(Figure 1) have been published. Allele frequencies above 20% were
observed in the eastern (29%) and western (24%) parts of Burkina
Faso. Apart from one survey in southern Ghana, frequencies above
10% were only observed across Burkina Faso and the adjacent
northern parts of Ghana, Togo and Benin (32 surveys). Although
HbC has been found in other parts of Africa (including Angola,
Kenya, Egypt and Algeria), none of the surveys conducted in
southern Cameroon (seven surveys) or southern Chad (three
surveys) reported its presence. In North America, HbC was found
both on theWest and East coast of the United States (18 surveys), but
was absent from eight of nine surveys in Mexico. In South America,
HbC was identified in most surveys conducted in Brazil (33 surveys)
and was commonly observed (14 out of 38 surveys) in Columbia,
Venezuela and FrenchGuiana. It was not observed in Peru, Bolivia or
Chile (15 surveys). Ten of the 13 surveys conducted in the Caribbean
islands reported the presence of HbC. In Europe, HbC was observed
in capital cities (London, Paris, Madrid, and Brussels) as well as in
parts of Sardinia, but not in Greece or Albania. In the Middle East,
surveys conducted on the eastern coast of Saudi Arabia, in eastern
Iraq and along the Pakistani coast each reported a few cases. In Asia,
none of the population surveys, including themicro-mapping survey
conducted in Sri Lanka, found HbC. No surveys were available from
Oceania.
Map. Our continuous map predicted HbC allele frequencies across
Africa. The predicted posterior mean is presented in Figure 2. The
maximum of the predicted posterior median HbC allele frequency
was 16.0% (interquartile range (IQR): 12.0%–21.0%) in the eastern
part of Burkina Faso. Median frequencies above 12.5% were
predicted around that area, as well as in north-eastern Ghana,
northern Togo and north-western Benin. We predicted median
frequencies above 7.5% in western Burkina Faso (up to 11.0%
(IQR: 8.0%–14.0%), remaining parts of northern Ghana and
Benin, as well as across most of Mali, eastern Mauritania and
southern Algeria. Median frequencies reached up to 5.0% in most
other parts of western Africa, despite pockets of low frequencies
(e.g. in Sierra Leone and Guinea-Bissau) and a sharp longitudinal
decrease across Nigeria. Themodel also predicted a corridor of mean
frequencies of about 1.0% between West Africa and Egypt, based on
the finding of HbC in the few surveys conducted in these areas of low
population density. Patches of median frequencies below 1% were
predicted in Gabon, eastern Angola, and Uganda. The uncertainty
associated with these predictions is shown in Figure 3. The IQR
distribution reflects the distribution and heterogeneity of the data.
It reaches values up to 11.0% (IQR: 9.0%–20.0%) in eastern Burkina
Faso. The IQR ismostly above 5.0% acrossMali and northernGhana,
Togo and Benin where very few surveys were available.
National and regional estimates of affected newborns. We
estimated that, in 2010, in Africa, 672,117 (IQR: 642,116-705,163)
and 28,703 babies (IQR: 26,027-31,958) were born with the AC and
CC genotypes respectively (Table 1). At the national scale, 56% of the
AC newborns were expected to be from Burkina Faso (131,454 [IQR:
117,825-146,173]), Ghana (98,153 [IQR: 87,225-110,939]) and
Nigeria (IQR: 148,423 [112,961-197,818]), and 76% of the CC
newborns in these three countries (Burkina Faso: 9,592 [IQR:
7,258-13,259]); Ghana: 4,707 [IQR: 3,601-6,546]) and Nigeria:
3,099 [IQR: 1,822-5,948]) and Mali (4,354 [IQR: 2,257-9,952]).
Validation statistics. The mean error, mean absolute error and root
mean square (RMS) error associated with our allele frequency
predictions were 0.012 1 0.026, 0.019 1 0.027, and 0.026 1 0.037,
respectively. The overall bias of the predictions is thus very small,
while their accuracy and precision can be considered as good. The
Figure 1 | Global distribution of surveys on HbC. Green dots and orange triangles indicate surveys which found HbC to be present and absent from the
population sample respectively. Created with ESRI ArcGIS 10.1.
www.nature.com/scientificreports
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Monte Carlo standard errors (SE) associated with the areal estimates
at regional and national levels respectively are shown in Supple-
mentary Table S1.
Discussion
It is expected that the global economic burden of the haemoglobino-
pathies on public health will increase over the coming decades20. In
order to assess this burden and to track spatial and temporal changes,
it is crucial to have a good knowledge of the distribution and number
of individuals affected by these disorders. The map of surveys on HbC
provides a summary of currently available data and highlights areas
where further research is needed. The predicted allele frequency maps
reflect the contemporary distribution of this disorder in Africa. The
newborn estimates give us a more precise idea of the public health
importance of HbC. Each result is discussed in detail below.
The originally confined distribution of HbCwas described as early
as the mid-1950s26 - only a few years after the first identification of
this particular haemoglobin variant1. Nevertheless, cartographic
refinements have been nearly absent since then. In 1967, Frank B.
Livingstone published impressively detailed maps of abnormal hae-
moglobins, which included HbC, but he did not publish equivalent
maps in the updated version of his database in 198527. Further, these
maps were discontinuous, both spatially (i.e. mapping data as points
but not predicting at unobserved locations) and quantitatively (i.e.
using a categorical allele frequency scale). In 1994, Cavalli-Sforza et al
created a continuous allele frequency map of HbC as part of their
suite of genetic maps28. The aim of the present study was to
incorporate the additional data collected over the last decades and
the technological improvements in mapping and modelling meth-
ods27–29, allowing to provide precision metrics for the first time.
The distribution of datapoints somehow summarises our current
knowledge of HbC. Although most of the surveys were conducted in
West Africa, where the highest frequencies are expected, their sample
sizes are usually limited. The presence of HbC in surveys in Brazil, the
United States and European capitals for which data were available (e.g.
London and Paris) reflect the presence of immigrants fromWest Africa
in these communities. More detailed data from Belgium suggest that
HbC carriers might also be identified in smaller cities (Boemer,
pers. com.) but no surveys focussed on non-urban areas where HbC
is likely to be absent due to lower levels of admixture. Because of the
small number of surveys available in the Middle East and of the pos-
sible misidentification of HbC and HbE with commonly used electro-
phoretic methods3, the eastern limit of the distribution of HbC is
unclear.
According to our input data and predicted maps, HbC reaches its
highest predicted frequencies in the western part of Burkina Faso.
Our model suggests that high frequencies (% 7.5%) might extend
across Burkina Faso, the northern parts of Ghana, Togo and Benin,
and acrossMali, easternMauritania and the southern part of Algeria.
In the absence of any data from this area this is only informed by the
common presence of HbC in northern Africa. Conducting popu-
lation surveys in this area, as well as in Coˆte d’Ivoire and northern
Ghana, would help refine knowledge of the extent of the distribution
of high HbC allele frequencies in West Africa.
Figure 2 | Summarymap ofHbCpredicted allele frequency inAfrica. Rastermap (5 km3 5 km) ofHbC allele frequency (posteriormean) generated by
a Bayesian model-based geostatistical framework. Created with ESRI ArcGIS 10.1.
www.nature.com/scientificreports
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It is usually considered that the HbS mutation occurred at least
twice in human history, once inAfrica and once in Asia30–33; although
several haplotypes have been identified for the HbC mutation, it is
assumed to have a single origin in western Africa15,34. A recent case
study conducted in Thailand suggested that one local haplotype
might indicate an independent non-African origin of HbC18. The
small number of cases identified so far, the absence of HbC in popu-
lation surveys included in our database for India and Southeast Asia,
and the absence of HbC in recent unpublished studies carried in
Cambodia, Malaysia and South China (Fucharoen, pers. com.) tend
to suggest that this haplotype would have a very limited distribution
and low frequency. Furthermore, not a single case of HbC was iden-
tified during the micro-mapping work conducted in Sri Lanka
(Weatherall, pers. com.). Further investigation into the hypothesis
of an independent HbC mutation in Southeast Asia and its fitness in
the presence of thalassaemias and haemoglobin E would provide a
valuable contribution to our understanding of epistatic interactions
between haemoglobinopathies35,36.
There is strong evidence for the protective effect of HbS against
clinical Plasmodium falciparum malaria37. It is usually assumed that
HbC also protects against malaria, but to a much lesser extent than
HbS as reflected by its relatively limited original distribution8. An
apparent inverse correlation between HbS and HbC allele frequen-
cies in West Africa has been described8,33,38. The map presented here
represents the contemporary distribution of HbC within Africa
which because of human migration over the last few centuries is less
useful than amap of pre-migration frequencies for investigating such
a correlation5. Such maps and investigations are planned in future
applications of this work. Furthermore, there is some evidence sug-
gesting that other genes might also affect the level of malaria protec-
tion conveyed by HbC39.
Global, regional and national estimates of population affected
represent important tools to assess the status of a particular disease,
to follow its changes over space and time, and to guide associated
public health policy. In 2008, Modell and Darlison published various
estimates, including the proportion of pregnant women with AC and
the number of CC conceptions, and derived service indicators for the
haemoglobin disorders19. Here, we overcome several methodological
limitations in order to provide updated newborn estimates. First, we
performed online searches covering the 1950–2010 period to include
recent data and selected data based on strict inclusion criteria to
exclude non-representative surveys. Second, each survey was geor-
eferenced as precisely as possible, enabling better representation of
spatial heterogeneity. Third, we used high-resolution population
Figure 3 | Uncertainty map in HbC predicted allele frequency in Africa. Interquartile range (50% probability) of the per-pixel predicted allele
frequency. Created with ESRI ArcGIS 10.1.
www.nature.com/scientificreports
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distribution data to relate these heterogeneities with the distribution
of human populations. Finally, we calculated our predictions within
a Bayesian MBG framework, which allowed calculation of the pre-
cision associated with our estimates.
Using 2003 UN demographics, Modell and Darlison estimated a
global total of 14,719 CC newborns including 14,227 (97%) in the
AFRO region (Table 1). Their estimates were conservative (i.e. min-
imum figures) and estimates for countries where no HbC data were
available were set to zero (e.g. Kenya or the Democratic Republic of
the Congo). No estimates were published for the AC newborns and
the precision of the estimates published was unknown. Our regional
estimate for CC newborns in 2010 is about twofold higher, at 28,703
newborns (31.8 for the 25%-quartile estimate and32.2 for the 75%-
quartile estimate). This large difference is mostly due to higher pre-
dictions in West African countries. Because of high heterogeneity in
HbC allele frequency, extrapolating an average allele frequency to a
national population can lead to an underestimation (or overestima-
tion) of the number of individuals affected. In Burkina Faso, most of
the survey data come from the western part where frequencies are
comparatively lower than in the eastern part of the country. Similarly,
there is very little data from the northern parts of Ghana, Togo and
Benin – countries in which HbC allele frequencies tend to gradually
increase across a latitudinal gradient (Ohene-Frempong, pers. com.).
Not accounting for the distribution of the surveys within West
African countries or their population distribution (i.e. high popu-
lation density in areas of low HbC frequency and low population
density in areas of high frequency will produce dramatically different
estimates compared to the reverse situation) could therefore result in
underestimating the number of newborns affected.
Although HbC causes only relatively mild clinical complications in
AC and CC individuals, a good knowledge of its distribution and allele
frequencies represents a useful tool to better assess its contribution,
Figure 4 | Schematic overview of the approach. Blue diamonds describe input data. Orange boxes denote models and experimental procedures. Green
rods indicate output data. Created with Microsoft Office Visio 2007.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 1671 | DOI: 10.1038/srep01671 6
through compound individuals with HbSC disease or HbC/b-thalas-
saemia, to the global burden of the haemoglobinopathies20,40. A
bespoke multi-allelic model, ideally using an age-correction based
on the mortality of SC individuals and accounting for deviation from
Hardy-Weinberg assumptions41,42, would be required to estimate the
number of SC newborns within a similar framework. The availability
of the map and estimates presented here for HbC, alongside similar
products developed for HbS22, will facilitate such a study. The current
lack of an updated database on the thalassaemias makes the calcula-
tion of the number of HbC/b-thalassaemia compound newborns cur-
rently difficult. These various limitations will be the focus of future
work.
Globally, our database suggests that human migrations are prob-
ably the main drivers shaping the contemporary distribution of the
haemoglobinopathies, exerting a greater influence than positive
selection driven by protection against malaria, which seems to have
been themain factor in the past5,33. Although selection is likely to still
influence the distribution of haemoglobinopathies in malarious
regions, this change could contribute to shaping their future distri-
butions, particularly in the context of epidemiological transition20
and malaria elimination43 efforts. The work presented here could
not fully reflect those changes in the distribution of HbC due to
the relative paucity of data outside of Africa. Nevertheless, our
map provides a unique picture of the current distribution of HbC
in Africa, while our estimates suggest that the annual number of AC
and CC newborns might have been largely underestimated prev-
iously. In the long term, additional data will allow creating a global
contemporarymap and calculating global estimates and the develop-
ment of a multi-allelic model would allow the calculation of similar
estimates for SC and C-bThal compound individuals, which have a
greater impact on clinical burden. This forms part of our plans for
further work on the haemoglobinopathies.
Methods
A schematic overview of the methods used is provided as Figure 4. The methodology
is briefly described below. Further details are available in the Supplementary
Information.
Data sources. To identify publications with HbC allele frequency data, we undertook
a comprehensive online data search using PubMed44, ISI Web of Knowledge45, and
Scopus46 bibliographic databases. The following keywords were used: ‘haemoglobin
C’ and ‘hemoglobin C’. Searches performed on May 3, 2011 returned 1,275, 558 and
1,827 references in PubMed, ISI Web of Science and Scopus respectively. After
duplicate removal, we identified 1,992 unique references which were then reviewed
according to inclusion criteria, the main ones being that: i) the source included
primary data onHbC frequency; ii) the population samples were representative of the
local communities (data from targeted screening or selected population samples, such
as Afro-Americans, were excluded) and iii) the survey location could be
georeferenced precisely5. Additional data from unpublished sources fulfilling these
criteria (particularly from the MalariaGEN Consortium)47 were also included in the
global database. When several surveys conducted at the same location met the
inclusion criteria, only the most representative one (based on a combination of
criteria including the year of the survey, the sample size and the diagnostic method)
was used. The list of data sources used is shown in the Supplementary Information
and the database is freely available online (http://www.map.ox.ac.uk).
Bayesian model-based geostatistical (MBG) framework.Numbers of A (neg) and C
(pos) alleles, based on the number of AA, AC and CC individuals found in each
population survey conducted on the African continent were used as input to the
model alongside the surveys’ geographic coordinates (latitude and longitude). For
studies reporting the absence of any haemoglobin variants, all individuals were
considered as AA. The model generated two distinct types of output across Africa:
estimates of HbC allele frequency for every 5 3 5 km pixel (i.e. estimates at point
locations), and estimates of AC and CC newborns within each African country (i.e.
estimates over areal units). In both cases, the full posterior predictive distribution
(PPD)24, was generated for the target quantity using 500,000 Markov chain Monte
Carlo (MCMC) iterations48. A complete description of the model is given in the
Supplementary Information.
Predicted distribution map in Africa. We assumed Hardy-Weinberg equilibrium
for the calculation of AC and CC individuals from the HbC predicted allele
frequency5,24. The mean and interquartile range (IQR; interval between the 25% and
75% percentiles of the PPD) maps were used to summarise the predictions and their
associated uncertainty, respectively, for each pixel in African countries.
Estimates of newborns affected in Africa. The AC and CC predicted frequencies
were weighted by i) high resolution (1 3 1 km) population data from the 2010-
adjusted beta version of the Global Rural UrbanMapping Project (GRUMP)49, and ii)
national crude birth rates for 2010, derived from the 2010 revision online population
database of the United Nations (UN) world population prospects50 (see
Supplementary Information). To allow assessment of uncertainty measures
associatedwith these aggregated population numbers, estimates were calculated using
sampling from the whole predictive distributions of areal integrals (not just the mean
summary map) within the area considered22,24,51. Areal estimates were calculated
independently for the regional and national predictions. Summary estimates
presented here include the median and IQR of the population predictions.
Model validation. Validation metrics were calculated by comparing the observed
allele frequency for a 10% random hold-out sample of the African subset with the
prediction output created from the remaining 90% of the African data5. The
validationmetrics were summarised by i) themean error, which indicates the average
distance between the actual data points and the predicted values; ii) themean absolute
error, which measures the average magnitude of the errors in the predicted values;
and iii) the root mean square (RMS) error29. These errors provide a measure of the
model’s overall bias, overall accuracy and overall precision, respectively. In order to
calculate the Monte Carlo standard error (SE)52 associated with the newborn
estimates, the areal calculations were repeated ten times at each scale (see
Supplementary Information).
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